The o2h human health knowledge intensive EIS fund focuses on investing in early-stage companies covering novel drug discovery, artificial intelligence, digital therapeutics, and enabling services.
Portfolio
4
companies
Kuano
Kuano combines quantum mechanics and AI to design targeted enzyme inhibitors.
PharmEnable
PharmEnable develops next-generation small molecule drugs for challenging disease targets using an artificial intelligence platform.
Oxford Drug Design
Oxford Drug Design develops novel cancer therapeutics using a proprietary computational and machine learning platform.
Sanome
Sanome develops an engine for clinically validated home testing diagnostics.
Sunil Shah
CEO
Ajit Guller
Marketing and PR
Ajit directs Cambridge Wide Open Week and handles marketing and PR at o2h Ventures. He brings extensive marketing and ecosystem experience from his time across the o2h group and digital agencies.
LinkedInMercia Ventures led the seed financing round with participation from several backers to support platform validation and team growth.
"Enzymes play a wide-ranging role in disease, but current technologies are unable to develop drugs to tackle most of them. Our team at Kuano recognised the need to overcome these limitations."
MP Healthcare led the pre-Series A financing to help fund the expansion of the company drug discovery pipeline in oncology and neurology.
"At PharmEnable, we believe that everyone deserves safe and effective treatments, and we are committed to applying the principles chemical novelty, diversity and 3-dimensionality to design powerful new small molecule drugs."
The financing round was backed by ACF Investors, o2h Ventures, Jonathan Milner, and R42 Group.
"This latest funding will enable us to build on and accelerate our successful computational design-led discovery focus. We are excited to be playing a pivotal role in the innovation of oncological treatments leading to better outcomes for cancer patients worldwide. Our groundbreaking new approach stands to be initially validated by the proof-of-concept studies. We are achieving rapid progress not only with our industry-leading drug discovery programme, but also our proprietary AI platform. This has led to increasing interest from third parties in our machine learning capabilities, so we are keen to capitalise on this demand and establish a commercial effort in this area"
The funding round was led by Heal Capital and will support team expansion and product development.
"Healthcare touches each and every one of us and the recent pandemic has highlighted that at a global level. It showed the need to bring healthcare closer to people’s homes and that we need to leverage many of the recent innovations in digital health and consumer biotech to capture as many data points about human health as possible. This will transform our understanding of the human body and our approach to disease detection and management. At Sanome we are working toward developing multiple at home health tools to drive disruption within the healthcare landscape to benefit each one of us"
The seed round was backed by ACF Investors, o2h Ventures, and angel investors to fund team expansion and platform development.
"With this investment, our investors have affirmed the strength of our technology and its commercial potential. Building upon years of research, this funding will drive the development of our platform, facilitate the rollout of our own range of therapeutics and expand our team. As our recent collaboration with the UCL Drug Discovery Institute has shown, we are beginning to have a potent effect on the pharmaceutical industry and I am looking forward to the many ways in which we can make a decisive contribution to medicine worldwide"
The biotechnology spin-out raised funds from backers including the Angel CoFund and o2h Ventures alongside Department of Health and Social Care grants.
"This latest funding further validates our computational design-led focus that has enabled rapid progress in building our pipeline of novel antibiotic programmes."
